The total return over the past 12 months is -56.33% vs. +16.94% for the S&P 500. So far it's up -20.91% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (56.33%) | (60.24%) | (71.86%) | N/A | N/A | N/A |
| Total Return CAGR | (56.33%) | (60.24%) | (71.86%) | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Adial Pharmaceuticals, Inc. (ADIL)
| Year | Start price | End price | ADIL Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $5.50 | $4.35 | (20.91%) | +14.51% | (35.42%) |
| 2025 | $25.25 | $5.50 | (78.22%) | +17.72% | (95.94%) |
| 2024 | $46.50 | $25.25 | (45.70%) | +24.89% | (70.59%) |
| 2023 | $137.50 | $46.50 | (66.18%) | +26.19% | (92.37%) |
| 2022 | $1,687.50 | $137.50 | (91.85%) | (18.17%) | (73.68%) |
| 2021 | $1,062.50 | $1,687.50 | +58.82% | +28.74% | +30.08% |
| 2020 | $1,506.25 | $1,062.50 | (29.46%) | +18.37% | (47.83%) |
| 2019 | $3,200.00 | $1,506.25 | (52.93%) | +31.22% | (84.15%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
